These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature. Malhotra K; Carrington DC; Liebeskind DS J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e172-e175. PubMed ID: 28647415 [TBL] [Abstract][Full Text] [Related]
4. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. Sacconi S; Bocquet JD; Chanalet S; Tanant V; Salviati L; Desnuelle C J Neurol; 2010 Oct; 257(10):1730-3. PubMed ID: 20559845 [TBL] [Abstract][Full Text] [Related]
5. Decreased outlet angle of the superior cerebellar artery as indicator for dolichoectasia in late onset Pompe disease. Hensel O; Schneider I; Wieprecht M; Kraya T; Zierz S Orphanet J Rare Dis; 2018 Apr; 13(1):57. PubMed ID: 29653542 [TBL] [Abstract][Full Text] [Related]
6. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy. Hossain MA; Miyajima T; Akiyama K; Eto Y J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3046-3052. PubMed ID: 30093193 [TBL] [Abstract][Full Text] [Related]
7. Obstructive sleep apnea in late-onset Pompe disease treated by enzyme replacement therapy. Bhui R; Spector AR Neuromuscul Disord; 2020 Apr; 30(4):329-330. PubMed ID: 32173248 [TBL] [Abstract][Full Text] [Related]
8. Intracranial vasculopathy: an important organ damage in young adult patients with late-onset Pompe disease. Zhao Y; Yu X; Li D; He J; Li Y; Zhang B; Zhang N; Wang Q; Yan C Orphanet J Rare Dis; 2024 Jul; 19(1):267. PubMed ID: 39010129 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983 [TBL] [Abstract][Full Text] [Related]
10. Cognitive Development in Infantile-Onset Pompe Disease Under Very Early Enzyme Replacement Therapy. Lai CJ; Hsu TR; Yang CF; Chen SJ; Chuang YC; Niu DM J Child Neurol; 2016 Dec; 31(14):1617-1621. PubMed ID: 27655474 [TBL] [Abstract][Full Text] [Related]
11. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031 [TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. But WM; Lee SH; Chan AO; Lau GT Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Forsha D; Li JS; Smith PB; van der Ploeg AT; Kishnani P; Pasquali SK; Genet Med; 2011 Jul; 13(7):625-31. PubMed ID: 21543987 [TBL] [Abstract][Full Text] [Related]
16. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years. Schänzer A; Görlach J; Claudi K; Hahn A Neuromuscul Disord; 2019 Jun; 29(6):477-482. PubMed ID: 31101460 [TBL] [Abstract][Full Text] [Related]